Viral diseases continue to pose some of the greatest challenges to modern medicine and therefore antiviral therapies are becoming an important, emerging area of pharmaceutical research. For many viral diseases, prophylactic vaccines are unlikely to be developed in the near future. Fortunately, effective antiviral therapies have been developed for many of these viruses. In this article, we decided to evaluate Chimerix, Inc. (NASDAQ:CMRX), a small-cap biopharmaceutical company engaged in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs.
Chimerix is based in Durham, North Carolina, and was founded in 1996. The company licensed lipid-conjugation technology from the University of California that has been shown to improve the potency of antivirals, and...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|